LIR-8/CD85c/LILRB5 Antibody (1058033) [Alexa Fluor® 532]

• Reactivity: Hu
• Applications: ICC/IF
• Clone: 1058033
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 532

LIR-8/CD85c/LILRB5 Antibody (1058033) [Alexa Fluor® 532] Summary

• Immunogen: Mouse myeloma cell line, NS0-derived human LILRB5/CD85c/LIR-8
  Arg18-His456
  Accession # O75023
• Specificity: Detects human LILRB5/CD87c/LIR-8 in direct ELISA.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for LIR-8/CD85c/LILRB5 Antibody (1058033) [Alexa Fluor® 532]

• CD85 antigen-like family member C
• CD85c antigen
• CD85c
• Leukocyte immunoglobulin-like receptor 8
• leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains)
• LILRB5
• LIR8
• LIR-8
• LIR8CD85C
• LIR-8leukocyte immunoglobulin-like receptor subfamily B member 5
• member 5

Background

LIR8, also known as CD85c and LILRB5, belongs to the Leukocyte immunoglobulin-like receptors (LILR) family of transmembrane glycoproteins involved in regulating immune responses (1,2). There are at least thirteen LILR family members and are divided into activating (LILRA) or inhibiting (LILRB) molecules (1, 2). Mature human LIR8 consists of an extracellular domain (ECD) with four Ig-like domains, a transmembrane segment, and a cytoplasmic domain with two immunoreceptor tyrosine-based inhibitory motifs (ITIM). Alternative splicing of human LIR8 generates at least 2 isoforms, one lacking the second Ig-like domain. The LILR family appears to be primate-specific receptors in terms of sequence homology. LIR8 is expressed on NK cells and in the tryptic granules of mast cells and negatively regulates immune cell activation (3, 4) It is present on the mast cell surface following cell activation and degranulation (4). Activated mast cells may also release soluble forms of LIR8 (3). LIR8 has also been shown to be expressed on T cells and induce CD8+ T cell proliferation (5). Consistent with the demonstrated binding of LILRB2 to Angiopoietin-like 2 and 5 (6), R&D Systems in-house testing indicates that LIR8 binds to Angiopoietin-like 7. Recently, a common missense variant of LIR8 was found to be associated with statin intolerance and myalgia (7).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.